Despite big improvements in survival, cancer is still one of the worlds biggest killers. Leading Cancer Research UK-funded scientists explain why it presents such a challenge and look at how far weve come
Written by Natalie Grover for Guardian Labs
Part of a pancreatic tumour seen down a microscope, with tumour cells labelled in green, and different types of immune cell in pink, yellow, red, and turquoise. Image credit: Silvia Cusumano, Assya Legrini, Leah Officer-Jones, Dr Nigel Jamison and Prof John La Quesne
Recent decades have yielded extraordinary progress in cancer survival, but many cancers remain deadly, with half of people diagnosed dying within 10 years. So why hasnt science found a way to cure more people yet?
A major challenge is that scientists arent in fact targeting a single disease but a constellation of hundreds of diseases that are lumped together under the umbrella classification of cancer. This came about because all cancers start in the same way, with mutations in genes that control cell function.
Such mutations can fuel the unfettered replication of a single cell. If conditions are right, the cell grows and divides, escalating to millions of cells that may clump together to form a tumour in which no two tumour cells are identical in a single tumour.
I might have been pessimistic that we would ever be able to control these rapidly multiplying clumps of cells, says Prof Sir Mike Stratton, director of the Wellcome Sanger Institute and a genetics expert.
But time and again, the achievements of cancer research have mitigated that pessimism and converted it to optimism. It isnt that one drug will wipe the whole lot [of cancers] off the map, but bit by bit we are eroding the mortality rates of many cancers.
Stratton, leader of the Cancer Grand Challenges Mutographs team, which is working on a 20m project to look for unknown causes of cancer, adds: Were learning that research finding out what is actually going on in cancer cells is the route to new strategies for undermining the ability of cancer cells to behave in the way that they do.
While cancers may start in the same way, decades of research have shown that they evolve into very different diseases requiring a panoply of treatments. So far, scientists have classified more than 200 types of cancer, and found a myriad of genetic mutations underlying them.
Out of around 20,000 genes in the human genome, between 500 and 1,000 have been identified as contributing, when mutated, to a cell becoming cancerous. There is, however, a set of cancers for which the genes are still unclear, says Stratton, who is credited with identifying the breast cancer susceptibility gene BRCA2 among others.
Its tempting to think that the way forward is to target all the genes known to be implicated in cancer by launching 500-plus drug development programmes.
But not only is this a huge task, its by no means certain that the drugs developed would be the answer to curing the different cancers. This is because tumours develop considerable genetic diversity as they evolve, and often become resistant to treatments as more mutations occur in cells.
Targeted therapies have been approved for a range of cancers including breast, liver and lung cancers, and are helping more people to live longer. For now, though, the search for more precision treatments goes on. There is a set of cancer genes that are switched off by their own mutations, Stratton says. So how do we use those genes in order to develop new therapies?
Cancer cells growing in 2D, labelled with fluorescent markers showing the cells nuclei in blue, their cytoplasm in red, and areas of DNA damage in green. Image credit: Getty Image
Drug resistance is one of the biggest challenges in cancer thats why its so important to diagnose cancers early when treatment is more likely to be successful, says our chief clinician Prof Charles Swanton, group leader at the Francis Crick Institute, co-director of the charitys Lung Cancer Centre of Excellence and a consultant at University College London Hospitals (UCLH).
Early diagnosis isnt always possible, for a range of reasons. For example, there are very few techniques that can detect small, early tumours, and some cancers simply dont trigger symptoms early enough until they have already spread (or metastasised) and it is at this stage that the oncologists toolkit of drugs often falls short.
Each cancer has a different suite of signals which its responding to
Robert Insall, professor of mathematical and computational biology
To help uncover the tricks that tumours deploy to evolve, spread and develop drug resistance, we are supporting the TRACERx clinical study for which Swanton is chief investigator. By following the progress of hundreds of patients with the most common form of lung cancer from the point of diagnosis onwards, the study views cancer through an evolutionary lens, and uses a vast array of cutting-edge techniques to monitor participants disease.
According to Swanton, the lessons already learned from tracking these patients are applicable to many types of cancer. For instance, the study has shown that tumours with a high level of genetic diversity have the worst clinical outcomes, and that tumours use an assortment of ploys to elude the immune system, including losing the flags on their cell surface that enable them to be recognised as problematic.
Overall, says Swanton, the major barriers to successfully treating metastatic cancer are the genetic diversity within tumours, the evolutionary fitness of cancer cells that allows them to adapt, and of increasing focus the ways tumours modify their local microenvironment to support their survival.
The tumour microenvironment is composed of non-malignant cells that have been hijacked by cancer cells to support and nourish the tumour. This allows the cancer to smother the bodys immune defence.
Prof Fran Balkwill
Typically, half of the cells that make up a tumour are non-cancerous, and include fibroblasts (for structural support), fat cells and endothelial cells (which can form blood vessels that deliver oxygen and nutrients, and eliminate waste), says Prof Fran Balkwill, whose work at the Barts Cancer Institute in London centres on the links between cancer and inflammation.
Better understanding of this microenvironment and potentially reprogramming it could restrict nourishment of this cancerous rogue organ and reawaken the bodys immune cells to recognise and destroy it.
Already this ecosystem of hijacked normal cells within tumours is being targeted by cancer treatments, whether immunotherapy or chemotherapy, says Balkwill, noting that it is likely that treatments in the future will be combinations of drugs that target malignant cells and this microenvironment.
What makes cancer ultimately so dangerous, however, is the suite of signals that induce it to move beyond its primary site into the blood, lymphatic system or other tissues.
Robert Insall, professor of mathematical and computational biology.
Typically, chemical signals steer a cancer cell to move in a particular direction, but in many cases we dont know what they are, says Robert Insall, professor of mathematical and computational cell biology at the our Beatson Institute in Glasgow. So, if youre looking at this theme of why isnt cancer cured yet, its because each cancer has a different suite of signals which its responding to.
In the case of melanoma, a serious form of skin cancer, Insalls research suggests that the cancer cells themselves make their own spreading signals, creating the local instructions that direct them to spread.
Other kinds of skin cancer are not nearly as scary because they either dont, or rarely, spread. And one of the reasons is that they are not primed to drive themselves outwards in the same way, he says. My suspicion is that the most metastatic, the most deadly, cancers have this same property [as melanoma].
Reprogramming a tumours microenvironment could reawaken the bodys immune cells to destroy it
Professor Fran Balkwill
Insights such as Insalls continue to inform research into the biology of cancer, building on the decades of endeavour that have gone before. This burgeoning knowledge has transformed the way doctors diagnose and treat cancers in the UK, for instance, survival rates have doubled in the past 40 years for all cancers combined. On this journey to cure patients with cancer, says Swanton, I think were about half way there.
Part of an ovarian tumour viewed down a microscope, with cancer cells in blue and immune cells in brown Barts Cancer Institute
The second half of this odyssey demands further research. Research that will not just benefit the cancer patients of tomorrow, but is keeping hope alive for people affected by cancer now who may have limited or no treatment options if their cancer progresses.
Eileen Rapley, a participant in the TRACERx study who is being treated at UCLH, and who has also been receiving an immunotherapy drug that has so far kept her cancer at bay, says: When youre diagnosed with cancer and youre suddenly very dependent on other people, being able to contribute something makes it a little more palatable. You feel that at least this cancer is having a positive effect rather than a negative one.
But funding for this type of lifesaving research has come under considerable strain, in large part due to the pandemic, with CRUK needing to reduce its planned spending for 2022-23 from 400m to 300m.
Maintaining investment in cancer research and getting back to where we were in 2017, 2018 and 2019 is going to be absolutely crucial, says Swanton.
We are now getting to the point of being able to personalise medicines given to patients upon the genetic basis of their disease, he says. But we need new medicines to circumvent and overcome drug resistance in cancers that have spread, and new approaches to detect small, early stage tumours, and treat them before they become malignant thats where some of the major advances are going to come from over the next five decades.
This article was originally published on theguardian.com as part of the Cancer Research UK and Guardian Labs Cancer revolutionaries campaign.
To dig deeper into why we havent cured cancer, we heard from Dr Alanna Skuse, Dr Mariam Jamal-Hanjani and Sir Leszek Borysiewicz in the latest episode of our podcast That Cancer Conversation.
From Egyptian mummies and medieval wolves, to precision medicine and microscopic evolution, we take a look at the past to find out why curing cancer is more complex than we think, and what is needed next to get us closer to a future without cancer.
Read the original post:
Why havent we cured cancer? - Cancer Research UK News
- Copy number variation of the restorer Rf4 underlies human selection ... - Nature.com - November 15th, 2023 [November 15th, 2023]
- NYU Langone Health in the NewsThursday, November 9, 2023 - NYU Langone Health - November 15th, 2023 [November 15th, 2023]
- Eugenics: Plaguing scientific community with dark history | Opinion ... - The Arkansas Traveler - November 15th, 2023 [November 15th, 2023]
- Cranberries can bounce, float and pollinate themselves: The saucy ... - Japan Today - November 15th, 2023 [November 15th, 2023]
- Government Housing Assistance Linked to Increased Cancer ... - HealthDay - November 15th, 2023 [November 15th, 2023]
- Rate of New Lung Cancer Cases Has Decreased Over Last Five Years - HealthDay - November 15th, 2023 [November 15th, 2023]
- Clinically relevant antibiotic resistance genes are linked to a limited ... - Nature.com - November 15th, 2023 [November 15th, 2023]
- Disparities in Guideline-Concordant Care Found for Black CRC ... - HealthDay - November 15th, 2023 [November 15th, 2023]
- Mathematician Heather Harrington is new director at the Max Planck ... - EurekAlert - November 15th, 2023 [November 15th, 2023]
- New study finds genetic testing can effectively identify patients with ... - EurekAlert - November 15th, 2023 [November 15th, 2023]
- STK11 loss leads to YAP1-mediated transcriptional activation in ... - Nature.com - November 15th, 2023 [November 15th, 2023]
- CRISPR-broad: combined design of multi-targeting gRNAs and ... - Nature.com - November 15th, 2023 [November 15th, 2023]
- Master regulator of the dark genome greatly improves cancer T-cell ... - Science Daily - November 15th, 2023 [November 15th, 2023]
- Omega Therapeutics Showcases Bidirectional and Multiplexed ... - BioSpace - November 15th, 2023 [November 15th, 2023]
- Today is International 15q Day - ASBMB Today - November 15th, 2023 [November 15th, 2023]
- Evolution of taste: Sharks were already able to perceive bitter ... - EurekAlert - November 15th, 2023 [November 15th, 2023]
- Stanford Scientists Uncover New Indicators of Health, Disease, and ... - SciTechDaily - October 16th, 2023 [October 16th, 2023]
- NHGRI Director Eric Green elected to the National Academy of ... - National Human Genome Research Institute - October 16th, 2023 [October 16th, 2023]
- Monkey survives for two years after gene-edited pig-kidney transplant - Nature.com - October 16th, 2023 [October 16th, 2023]
- Opinion: Interest in RNA Editing Accelerates as Therapies Approach ... - BioSpace - October 16th, 2023 [October 16th, 2023]
- Regulation of dermal fibroblasts by human neutrophil peptides ... - Nature.com - October 16th, 2023 [October 16th, 2023]
- Consistent effects of the genetics of happiness across the lifespan ... - Nature.com - October 16th, 2023 [October 16th, 2023]
- Storytelling through the looking glass of genetics The Stute - The Stute - October 16th, 2023 [October 16th, 2023]
- Pet dogs shed light on human health, researchers say - UPI News - October 16th, 2023 [October 16th, 2023]
- Native microbiome dominates over host factors in shaping the ... - Nature.com - October 16th, 2023 [October 16th, 2023]
- Illinois-led project to sequence soybean genomes, improve future ... - Herald-Whig - October 16th, 2023 [October 16th, 2023]
- Unrealized targets in the discovery of antibiotics for Gram-negative ... - Nature.com - October 16th, 2023 [October 16th, 2023]
- How Biotech And AI Are Transforming The Human - Noema Magazine - October 16th, 2023 [October 16th, 2023]
- The Many Lives of Alexandria Forbes - BioSpace - October 16th, 2023 [October 16th, 2023]
- CEP20 promotes invasion and metastasis of non-small cell lung ... - Nature.com - October 16th, 2023 [October 16th, 2023]
- Genotyping, sequencing and analysis of 140,000 adults from Mexico ... - Nature.com - October 16th, 2023 [October 16th, 2023]
- The role and impact of alternative polyadenylation and miRNA ... - Nature.com - October 16th, 2023 [October 16th, 2023]
- Human - Simple English Wikipedia, the free encyclopedia - January 30th, 2023 [January 30th, 2023]
- Deep Dive Ties Together Dog Genetics, Brain Physiology and Behavior to Explain Why Collies Are Different from Terriers - Scientific American - December 12th, 2022 [December 12th, 2022]
- How oxytocin drives connections of newly integrated adult-born neurons: Research - Hindustan Times - December 12th, 2022 [December 12th, 2022]
- Alzheimer's Disease Genetics Fact Sheet - National Institute on Aging - December 2nd, 2022 [December 2nd, 2022]
- Human genetic clustering - Wikipedia - November 23rd, 2022 [November 23rd, 2022]
- Human Genome Project Fact Sheet - November 23rd, 2022 [November 23rd, 2022]
- Abstracts | International Congress of Human Genetics 2023 - November 23rd, 2022 [November 23rd, 2022]
- Ancient DNA and Neanderthals | The Smithsonian Institution's Human ... - November 16th, 2022 [November 16th, 2022]
- Biological Influences on Human Behavior: Genetics & Environment - November 16th, 2022 [November 16th, 2022]
- Fluent BioSciences showcasing breakthrough solutions to enable unprecedented scale, cost-efficiency and access for single-cell RNA sequencing at the... - October 28th, 2022 [October 28th, 2022]
- Human behaviour genetics - Wikipedia - October 23rd, 2022 [October 23rd, 2022]
- Nucleome Therapeutics raises oversubscribed 37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class... - October 19th, 2022 [October 19th, 2022]
- Gladstone data scientist elected to the National Academy of Medicine - EurekAlert - October 19th, 2022 [October 19th, 2022]
- Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022 - Yahoo Finance - October 19th, 2022 [October 19th, 2022]
- Pharmacy researcher earns $2.3 million NIH award to study opioid addiction - EurekAlert - October 19th, 2022 [October 19th, 2022]
- Study shows age often plays a bigger role than genetics in gene expression and susceptibility to disease - Anti Aging News - October 19th, 2022 [October 19th, 2022]
- CSRWire - Direct Relief, Amgen and C/Can Team Up To Improve Access to Breast Cancer Diagnostics and Treatment in Paraguay - CSRwire.com - October 19th, 2022 [October 19th, 2022]
- Maze Therapeutics Appoints Harold Bernstein, M.D., Ph.D., as President, Research and Development and Chief Medical Officer - Business Wire - October 19th, 2022 [October 19th, 2022]
- New Rare Disease Therapy Effectively Lowers Plasma Phe in Patients with PKU - MD Magazine - October 19th, 2022 [October 19th, 2022]
- GSK : announces expanded collaboration with Tempus in precision medicine to accelerate R&D - Marketscreener.com - October 19th, 2022 [October 19th, 2022]
- Famous Scientific Discoveries That Changed the Course of History - 24/7 Wall St. - October 19th, 2022 [October 19th, 2022]
- Construction workers seek fulfilment of their demands - Star of Mysore - October 19th, 2022 [October 19th, 2022]
- Genetics | The Smithsonian Institution's Human Origins Program - October 13th, 2022 [October 13th, 2022]
- Genetics - Wikipedia - October 13th, 2022 [October 13th, 2022]
- Study looking at human genetics and Covid vaccine immune responses - Science Media Centre - October 13th, 2022 [October 13th, 2022]
- ASHG 2022 in Los Angeles brings together researchers from around the world to advance discoveries in genetics, genomics research - EurekAlert - October 13th, 2022 [October 13th, 2022]
- Maze Therapeutics Appoints Harold Bernstein, M.D., Ph.D., as President, Research and Development and Chief Medical Officer - Yahoo Finance - October 13th, 2022 [October 13th, 2022]
- The Age of the Pangenome Dawns - DNA Science - PLOS - October 13th, 2022 [October 13th, 2022]
- Influence of the microbiome, diet and genetics on inter-individual variation in the human plasma metabolome - Nature.com - October 13th, 2022 [October 13th, 2022]
- Genome editing technologies: final conclusions of the re-examination of Article 13 of the Oviedo Convention - Council of Europe - October 13th, 2022 [October 13th, 2022]
- Global Biobank Meta-analysis Initiative making genome-wide association studies more diverse and representative - EurekAlert - October 13th, 2022 [October 13th, 2022]
- New NHS genetic testing service could save thousands of children in England - The Guardian - October 13th, 2022 [October 13th, 2022]
- Covid protection may be boosted by genes, study shows - Yahoo News Australia - October 13th, 2022 [October 13th, 2022]
- Genomics in Cancer Care Market is estimated to be US$ 72.61 billion by 2032 with a CAGR of 16.3% during the forecast period 2032 - By PMI -... - October 13th, 2022 [October 13th, 2022]
- Identification of hub genes and candidate herbal treatment in obesity through integrated bioinformatic analysis and reverse network pharmacology |... - October 13th, 2022 [October 13th, 2022]
- Our *Homo sapiens* ancestors shared the world with Neanderthals, Denisovans and other types of humans whose DNA lives on in our genes -... - October 8th, 2022 [October 8th, 2022]
- Blue Eyed People Have a Single Ancestor | History of Yesterday - History of Yesterday - October 6th, 2022 [October 6th, 2022]
- Heart infection could be cause of death of Polish, US hero - ABC News - October 6th, 2022 [October 6th, 2022]
- 23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for... - October 6th, 2022 [October 6th, 2022]
- The Genetic Drivers Of Longevity In Mice, Humans And Worms - Science 2.0 - October 6th, 2022 [October 6th, 2022]
- ANGPTL7, a therapeutic target for increased intraocular pressure and glaucoma | Communications Biology - Nature.com - October 6th, 2022 [October 6th, 2022]
- 'Neanderthal Man' Nobel Prize winner Svante Pbo revolutionized anthropology. Here is a look back at his groundbreaking 2014 memoir - Genetic Literacy... - October 6th, 2022 [October 6th, 2022]
- Understanding Human Genetic Variation - NCBI Bookshelf - September 14th, 2022 [September 14th, 2022]
- Genetics - National Institute of General Medical Sciences (NIGMS) - September 14th, 2022 [September 14th, 2022]
- People with ME invited to take part in major genetic study - The Independent - September 14th, 2022 [September 14th, 2022]
- Ketamine Promising for Rare Condition Linked to Autism - Medscape - September 14th, 2022 [September 14th, 2022]
- How a small, unassuming fish helps reveal gene adaptations - University of Wisconsin-Madison - September 14th, 2022 [September 14th, 2022]
- How Nutrigenomics Explores Links Between Nutrition And Genes - Health Digest - September 14th, 2022 [September 14th, 2022]